Form 8-K - Current report:
SEC Accession No. 0001193125-22-242001
Filing Date
2022-09-09
Accepted
2022-09-09 16:30:01
Documents
14
Period of Report
2022-09-08
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d382794d8k.htm   iXBRL 8-K 25552
2 EX-99.1 d382794dex991.htm EX-99.1 8362
6 GRAPHIC g382794g0909105804447.jpg GRAPHIC 2957
  Complete submission text file 0001193125-22-242001.txt   159210

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nerv-20220908.xsd EX-101.SCH 2884
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nerv-20220908_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nerv-20220908_pre.xml EX-101.PRE 10831
8 EXTRACTED XBRL INSTANCE DOCUMENT d382794d8k_htm.xml XML 3236
Mailing Address 1601 TRAPELO ROAD SUITE 286 WALTHAM MA 02451
Business Address 1601 TRAPELO ROAD SUITE 286 WALTHAM MA 02451 617-600-7373
Minerva Neurosciences, Inc. (Filer) CIK: 0001598646 (see all company filings)

EIN.: 260784194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36517 | Film No.: 221236503
SIC: 2834 Pharmaceutical Preparations